Drug intelligence / Profile preview

QRX006

Development stage: Preclinical
Lead developer: Quoin Pharmaceuticals

Overview

QRX006 is a preclinical topical drug candidate being developed by Quoin Pharmaceuticals for an undisclosed rare dermatologic disease. Public disclosures describe it only as a therapy for rare skin disease, without specifying the molecular target, active ingredient, formulation, or precise indication, but it is part of Quoin’s portfolio of small‑molecule, topical products for orphan skin conditions such as Netherton syndrome and epidermolysis bullosa.[1][2][4][5]

Beyond the preview

Go deeper on QRX006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QRX006.

Explore the full profile